ACM
Aquilo Capital Management Portfolio holdings
AUM
$37.1M
This Quarter Return
+31.74%
1 Year Return
-36.49%
3 Year Return
+1.32%
5 Year Return
+39.69%
10 Year Return
–
AUM
$335M
AUM Growth
+$335M
(+37%)
Cap. Flow
-$11.8M
Cap. Flow
% of AUM
-3.52%
Top 10 Holdings %
Top 10 Hldgs %
92.74%
Holding
20
New
2
Increased
5
Reduced
7
Closed
2
Top Buys
| 1 |
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
|
$11.3M |
| 2 |
Dianthus Therapeutics
DNTH
|
$10.3M |
| 3 |
Galapagos
GLPG
|
$3.71M |
| 4 |
uniQure
QURE
|
$2.56M |
| 5 |
Genmab
GMAB
|
$1.63M |
Top Sells
| 1 |
Arrowhead Research
ARWR
|
$12.1M |
| 2 |
Spero Therapeutics
SPRO
|
$11M |
| 3 |
ProQR Therapeutics
PRQR
|
$10.9M |
| 4 |
AnaptysBio
ANAB
|
$5.63M |
| 5 |
AC Immune
ACIU
|
$2.26M |
Sector Composition
| 1 | Healthcare | 91.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Spero Therapeutics
SPRO
$116M
| $76.2M | 15.85% |
3,932,209
-564,933
| -13% | -$11M |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $42.6M | 8.86% |
380,012
-5,715
| -1% | -$641K |
|
|
NGM
3
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $30.5M | 6.33% |
1,005,534
-12,800
| -1% | -$388K |
|
|
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $29.9M | 6.21% |
1,355,392
-19,384
| -1% | -$427K |
|
|
5
Arrowhead Research
ARWR
$3.05B
| $28.1M | 5.84% |
365,926
-157,489
| -30% | -$12.1M |
|
|
6
AnaptysBio
ANAB
$569M
| $26.1M | 5.43% |
1,215,958
-261,694
| -18% | -$5.63M |
|
|
7
uniQure
QURE
$896M
| $25.4M | 5.27% |
702,050
+70,990
| +11% | +$2.56M |
|
8
Regenxbio
RGNX
$451M
| $22.8M | 4.75% |
503,444
-7,316
| -1% | -$332K |
|
|
9
Dianthus Therapeutics
DNTH
$759M
| $17.8M | 3.69% |
2,266,423
+1,307,805
| +136% | +$10.3M |
|
|
AMYT
10
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $11.3M | 2.35% |
+800,000
| New | +$11.3M |
|
|
PVLA
11
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $9.19M | 1.91% |
3,675,530
| – | – |
|
|
12
Galapagos
GLPG
$2.07B
| $6.93M | 1.44% |
69,989
+37,455
| +115% | +$3.71M |
|
13
argenx
ARGX
$43.6B
| $3.74M | 0.78% |
12,700
+5,200
| +69% | +$1.53M |
|
|
14
Genmab
GMAB
$15.3B
| $3.66M | 0.76% |
90,000
+40,000
| +80% | +$1.63M |
|
15
4D Molecular Therapeutics
FDMT
$288M
| $829K | 0.17% |
+20,000
| New | +$829K |
|
|
16
AC Immune
ACIU
$205M
| – | – |
-463,575
| Closed | -$2.26M |
|
17
iShares Biotechnology ETF
IBB
$5.6B
| – | – |
0
| – | – |
|
18
iShares Russell 2000 ETF
IWM
$67B
| – | – |
0
| – | – |
|
|
19
ProQR Therapeutics
PRQR
$237M
| – | – |
-2,281,966
| Closed | -$10.9M |
|
20
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|